Cassava Sciences Alzheimer's disease therapy late-stage trial progress approved by DSMB
I'm PortAI, I can summarize articles.
Cassava Sciences announced that its late-stage clinical trial for Alzheimer's disease has received approval from the Data and Safety Monitoring Board (DSMB) to continue without modification. The company's mid-term safety MRI data released in October 2023 indicated that simufilam is not associated with amyloid-related imaging abnormalities seen in treatment. This news has attracted attention from investment institutions and the medical community, leading to a more than 2% increase in the stock price during pre-market trading on the US stock market
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments